Last reviewed · How we verify
Intramuscular olanzapine, aripiprazole
Olanzapine and aripiprazole are atypical antipsychotics that block dopamine and serotonin receptors to reduce psychotic symptoms and agitation.
Olanzapine and aripiprazole are atypical antipsychotics that block dopamine and serotonin receptors to reduce psychotic symptoms and agitation. Used for Schizophrenia, Bipolar disorder (acute agitation or maintenance), Acute agitation in psychotic disorders.
At a glance
| Generic name | Intramuscular olanzapine, aripiprazole |
|---|---|
| Also known as | Olanzapine -> Aripiprazole |
| Sponsor | Veterans Medical Research Foundation |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor; serotonin 5-HT2A receptor (olanzapine); dopamine D2 partial agonist (aripiprazole) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Olanzapine antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors, while aripiprazole acts as a dopamine D2 partial agonist and serotonin 5-HT1A partial agonist. The intramuscular formulation provides rapid onset and sustained therapeutic levels, making it suitable for acute agitation or maintenance treatment in patients with schizophrenia, bipolar disorder, or other psychotic disorders.
Approved indications
- Schizophrenia
- Bipolar disorder (acute agitation or maintenance)
- Acute agitation in psychotic disorders
Common side effects
- Sedation
- Weight gain
- Extrapyramidal symptoms
- Orthostatic hypotension
- Metabolic syndrome
- Injection site reactions
Key clinical trials
- Examining the Effects of Antipsychotic Medications on Insulin Sensitivity (PHASE4)
- Acute Impact of Intramuscular (IM) Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: